Journal article
Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients
Breast cancer research and treatment, v 201(3), pp 571-576
01 Oct 2023
PMID: 37490173
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Purpose
Apolipoprotein M (APOM) is a plasma apolipoprotein closely involved with lipid metabolism and inflammation. In vitro studies suggest that APOM may also have a tumor-suppressive role in breast cancer. In the present study, we aimed to evaluate the impact of plasma APOM levels on the prognosis of breast cancer patients.
Methods
We measured APOM levels using an enzyme-linked immunosorbent assay in 75 patients with ER-positive/HER2-negative metastatic breast cancer. The endpoint was overall survival (OS) at 24 months.
Results
During the 24-month follow-up period, 34.7% of the patients died. Baseline APOM levels were significantly reduced in patients who deceased during follow-up compared to survivors (42.7 & PLUSMN; 14.5 & mu;g/mL versus 52.2 & PLUSMN; 13.8 & mu;g/mL; P = 0.003). Cox regression analysis showed a hazard ratio of 0.30 [95% confidence interval 0.15-0.61]; P < 0.001 per doubling of APOM levels. Correction for age, C-reactive protein, menopausal state, histology of the primary tumor, metastatic site, number of metastases, endocrine resistance, scheduled therapy line, and kind of scheduled therapy indicated that circulating APOM predicted OS independently of these parameters (HRper doubling = 0.23 [0.09-0.56; P = 0.001).
Conclusions
Our study suggests that circulating APOM is significantly linked with reduced mortality in metastatic breast cancer patients.
Metrics
Details
- Title
- Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients
- Creators
- Axel Muendlein - Vorarlberg Institute for Vascular Investigation and TreatmentChristine Heinzle - Vorarlberg Institute for Vascular Investigation and TreatmentEva Maria Brandtner - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Leiherer - Vorarlberg Inst Vasc Invest & Treatment Lab, Stadtstr 33, A-6850 Dornbirn, AustriaKathrin Geiger - Vorarlberg Inst Vasc Invest & Treatment Lab, Stadtstr 33, A-6850 Dornbirn, AustriaStella Gaenger - Vorarlberg Institute for Vascular Investigation and TreatmentHeinz Drexel - Drexel University, College of MedicineTobias Dechow - Ravensburg University of Cooperative EducationThomas Decker - Ravensburg University of Cooperative Education
- Publication Details
- Breast cancer research and treatment, v 201(3), pp 571-576
- Publisher
- Springer Nature
- Number of pages
- 6
- Grant note
- ABH055 / European Regional Development Fund through the INTERREG V program 'Alpenrhein-Bodensee-Hochrein'; Interreg Europe
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001035498500004
- Scopus ID
- 2-s2.0-85165654373
- Other Identifier
- 991021861306004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Oncology